fisogatinib (BLU-554) / Blueprint Medicines, CStone Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
fisogatinib (BLU-554) / Blueprint Medicines
NCT02508467: A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

Hourglass Sep 2020 - Sep 2020 : From trial for hepatocellular carcinoma at CSCO 2020
Hourglass Jul 2018 - Dec 2018 : Expansion cohort and TKI-naive cohort data
Checkmark P1 data in HCC at ESMO 2017 [screenshot]
Sep 2017 - Sep 2017: P1 data in HCC at ESMO 2017 [screenshot]
Checkmark For HCC at ENA 2016
More
Completed
1
146
Europe, US, RoW
Fisogatinib (BLU-554), BLU-554
Blueprint Medicines Corporation
Hepatocellular Carcinoma (HCC)
06/21
02/24
ChiCTR1900023266: A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma

Not yet recruiting
1
40
 
It is anticipated that patients will receive at least 1 cycle of BLU?554（subject will take 600mg qd）; no maximum treatment duration has been set. After C1, patients may continue to receive BLU?554 until precluded by toxicity, noncompliance, progressive disease, withdrawal of consent, death, or closure of the st
The Chinese People's Liberation Army 81th Hospital; West China Hospital, Sichuan University, Blueprint Medicines，Cstone
Hepatocellular carcinoma
 
 

Download Options